Biobanco

María Jesús Artiga Jefe de Unidad
T +34 917328000 (Ext 3650)
mjartiga@cnio.es

Técnicos de Laboratorio

Daniel Alba
Inmaculada Almenara
Ángela Alonso
Naiara Atenea Calero
María del Pilar Caro
Sergio Fernández
Elena Milagrosa Molina
Carmen Ortega
Cecilia Sobrino
Francisco Javier Soriano

CNIO Biobank is a cross-functional technological platform dedicated to facilitating access to high-quality human biological samples and their associated data for cancer and related disease research. Its primary mission is to support both CNIO researchers and the broader scientific community by ensuring that sample acquisition and usage adhere strictly to legal and ethical standards, safeguarding donors’ rights throughout the process.

As a comprehensive service platform, CNIO Biobank offers a wide array of resources that span all phases of research project management involving human samples. These include sample collection, processing, quality assurance, ethical and legal guidance, strategic acquisition and design of research collections, and stakeholder engagement to identify suitable samples or assist in securing ethical approvals.

CNIO Biobank is officially authorised by the Health Department of the Autonomous Community of Madrid and is registered with the National Biobank Registry of the Instituto de Salud Carlos III (Ref: B.848).

Publicaciones recientes

Serra-Llovich A et al. (incl. Artiga MJ, Molina E and Ortega-Paino E for the Scourge Cohort Group) (2025). Pharmacogenomic Study of SARS-CoV-2 Treatments: Identifying Polymorphisms Associated with Treatment Response in COVID-19 Patients. Biomedicines 13, 553. Publicación CNIO.
Diz-de Almeida S, Cruz R, Luchessi AD, Lorenzo-Salazar JM, de Heredia ML, Quintela I, González-Montelongo R, Nogueira Silbiger V, Porras MS, Tenorio Castaño JA, Nevado J, Aguado JM, Aguilar C, Aguilera-Albesa S, Almadana V, Almoguera B, Alvarez N, Andreu-Bernabeu Á, Arana-Arri E, Arango C, Arranz MJ, Artiga MJ, Baptista-Rosas RC, Barreda-Sánchez M, Belhassen-Garcia M, Bezerra JF, Bezerra MAC, Boix-Palop L, Brion M, Brugada R, Bustos M, Calderón EJ, Carbonell C, Castano L, Castelao JE, Conde-Vicente R, Cordero-Lorenzana ML, Cortes-Sanchez JL, Corton M, Darnaude MT, De Martino-Rodríguez A, Del Campo-Pérez V, de Bustamante AD, Domínguez-Garrido E, Eirós R, Fariñas MC, Fernandez-Nestosa MJ, Fernández-Robelo U, Fernández-Rodríguez A, Fernández-Villa T, Gago-Dominguez M, Gil-Fournier B, Gómez-Arrue J, Álvarez BG, Bernaldo de Quirós FG, González-Neira A, González-Peñas J, Gutiérrez-Bautista JF, Herrero MJ, Herrero-Gonzalez A, Jimenez-Sousa MA, Lattig MC, Borja AL, Lopez-Rodriguez R, Mancebo E, Martín-López C, Martín V, Martinez-Nieto O, Martinez-Lopez I, Martinez-Resendez MF, Martinez-Perez A, Mazzeu JF, Macías EM, Minguez P, Cuerda VM, Oliveira SF, Ortega-Paino E, Parellada M (2024). Novel risk loci for COVID-19 hospitalization among admixed American populations. Elife 13, RP93666. Publicación CNIO.
de Melo-Martín I, Ortega-Paíno E. (2024). Biobanking Legislation in Spain: Advancing or Undermining Its Ethical Values?. Biopreservation & Biobanking 22, 242-247. Publicación CNIO.
COVID-19 Host Genetics Initiative. (2023). A second update on mapping the human genetic architecture of COVID-19.. Nature 621, E7-E26. Publicación CNIO. Open Access
Pairo-Castineira E, Rawlik K, Bretherick AD, Qi T, Wu Y, Nassiri I, McConkey GA, Zechner M, Klaric L, Griffiths F, Oosthuyzen W, Kousathanas A, Richmond A, Millar J, Russell CD, Malinauskas T, Thwaites R, Morrice K, Keating S, Maslove D, Nichol A, Semple MG, Knight J, Shankar-Hari M, Summers C, Hinds C, Horby P, Ling L, McAuley D, Montgomery H, Openshaw PJM, Begg C, Walsh T, Tenesa A, Flores C, Riancho JA, Rojas-Martinez A, Lapunzina P; GenOMICC Investigators; SCOURGE Consortium; ISARICC Investigators; 23andMe COVID-19 Team; Yang J, Ponting CP, Wilson JF, Vitart V, Abedalthagafi M, Luchessi AD, Parra EJ, Cruz R, Carracedo A, Fawkes A, Murphy L, Rowan K, Pereira AC, Law A, Fairfax B, Hendry SC, Baillie JK. (2023). GWAS and meta-analysis identifies 49 genetic variants underlying critical COVID-19.. Nature 671, 764-768. Publicación CNIO. Open Access
Sanchez-Aguilera A, Masmudi-Martín M, Navas-Olive A, Baena P, Hernández-Oliver C, Priego N, Cordón-Barris L, Alvaro-Espinosa L, García S, Martínez S, Lafarga M; RENACER; Lin MZ, Al-Shahrour F, Menendez de la Prida L, Valiente M (2023). Machine learning identifies experimental brain metastasis subtypes based on their influence on neural circuits. Cancer Cell 41, 1637-1649. Publicación CNIO. Open Access
Castro-Santos P, Rojas-Martinez A, Riancho JA, Lapunzina P, Flores C, Carracedo Á, Díaz-Peña R; Scourge Cohort Group (2023). HLA-A*11:01 and HLA-C*04:01 are associated with severe COVID-19. . HLA. 2023 Dec;102(6):731-739. doi: 10.1111/tan.15160. Epub 2023 Aug 1. PMID: 37528566. HLA 102, 731-739. Publicación CNIO.
Valiente M, Ortega-Paino E (2023). Updating cancer research with patient-focused networks. Trends in Cancer (in press). Publicación CNIO. Open Access
Zhu L, Retana D, García-Gómez P, Álvaro-Espinosa L, Priego N, Masmudi-Martín M, Yebra N, Miarka L, Hernández-Encinas E, Blanco-Aparicio C, Martínez S, Sobrino C, Ajenjo N, Artiga MJ, Ortega-Paino E, Torres-Ruiz R, Rodríguez-Perales S; RENACER, Soffietti R, Bertero L, Cassoni P, Weiss T, Muñoz J, Sepúlveda JM, González-León P, Jiménez-Roldán L, Moreno LM, Esteban O, Pérez-Núñez Á, Hernández-Laín A, Toldos O, Ruano Y, Alcázar L, Blasco G, Fernández-Alén J, Caleiras E, Lafarga M, Megías D, Graña-Castro O, Nör C, Taylor MD, Young LS, Varešlija D, Cosgrove N, Couch FJ, Cussó L, Desco M, Mouron S, Quintela-Fandino M, Weller M, Pastor J, Valiente M. (2022). A clinically compatible drug-screening platform based on organotypic cultures identifies vulnerabilities to prevent and treat brain metastasis. EMBO Mol Med 14, 14552. Publicación CNIO. Open Access